lung cancer

envie a um amigo share this

Germline Genetic Variants of the Renin-Angiotensin System, Hypoxia and Angiogenesis in Non-Small Cell Lung Cancer Progression

The presence of polymorphic gene variants in the human genome provides extensive genetic (and eventually phenotypic) variation affecting both normal physiological mechanisms and cancer pathogenesis. Functional genetic polymorphisms might have predictive and/or prognostic value in lung cancer, opening novel opportunities to improve prediction and guide clinical reasoning and therapeutics in lung cancer patients.

Germline Genetic Variants of the Renin-Angiotensin System, Hypoxia and Angiogenesis in Non-Small Cell Lung Cancer Progression

The presence of polymorphic gene variants in the human genome provides extensive genetic (and eventually phenotypic) variation affecting both normal physiological mechanisms and cancer pathogenesis. Functional genetic polymorphisms might have predictive and/or prognostic value in lung cancer, opening novel opportunities to improve prediction and guide clinical reasoning and therapeutics in lung cancer patients.

EACR-OECI Joint Virtual Conference: Molecular Pathology Approach to Cancer

EACR-OECI Joint Virtual Conference: Molecular Pathology Approach to Cancer

Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling

Authors and Affiliations:

Ana Raquel-Cunha 1,2, Diana Cardoso-Carneiro 1,2, Rui M. Reis 1,2,3 and Olga Martinho 1,2,3*

1- Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal;

2 - ICVS/3Bs-PT Government Associate Laboratory, Braga/Guimarães, Portugal;

3 - Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil

 

Abstract:

Estado atual da proteína inibidora da quinase RAF1 (RKIP) em cancro do pulmão: na retaguarda da sinalização mediada por RTK’s

A equipa liderada por Olga Martinho, do Instituto de Investigação em Ciências da Vida e Saúde (ICVS) da Universidade do Minho, focou esta revisão no estado da arte sobre a proteína RKIP em cancro do pulmão, tendo apresentando ainda alguns dados originais resultantes de uma análise in silico usando a base de dados do TCGA.  A proteína inibidora da quinase RAF1 (RKIP) é uma importante moduladora de vias de sinalização intracelular relevantes, incluindo aquelas controladas pelo EGFR, como a via das MAPK.

Brief review of therapeutic innovations in the treatment of lung cancer

The discovery of crucial misexpressed genes in lung cancer allows a better understanding about the tumor microenvironment and the biomarkers that are a genetic fingerprint of this cancer. These biomarkers provide relevant knowledge to start the development of targeted therapies, overcoming the side effects and the development of resistances associated with the conventional treatments. Gene therapy and RNAi-based drugs are pointed out as promising and exciting new approaches to treat lung cancer.

Breve revisão de inovações terapêuticas no tratamento do cancro do pulmão

A descoberta de genes cruciais e mal-expressos no cancro de pulmão permite um melhor entendimento do microambiente do tumor e dos biomarcadores que são uma impressão genética desse cancro. Esses biomarcadores fornecem um conhecimento relevante para iniciar o desenvolvimento de terapias direcionadas, superando os efeitos colaterais e o desenvolvimento de resistências associadas aos tratamentos convencionais. A terapia génica e os medicamentos baseados em RNAi são apontados como novas e promissoras abordagens para o tratamento do cancro de pulmão.

Disruption of mitochondrial function as mechanism for anti-cancer activity of a novel mitochondriotropic menadione derivative

Authors and Affiliations:

José Teixeira1,2, Ricardo Amorim1, Katia Santos2, Pedro Soares1, Sandipan Datta3, Gino A. Cortopassi3, Teresa L. Serafim2, Vilma A. Sardão2, Jorge Garrido1,4, Fernanda Borges1, Paulo J. Oliveira2

CIQUP/Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Porto, Portugal

High systemic IL-6 is associated with worse prognosis in patients with non-small cell lung cancer

Authors and Affiliations:

Estela Maria Silva1#, Vânia Sammartino Mariano1#, Paula Roberta Aguiar Pastrez1, Miguel Cordoba Pinto2, António Gil Castro3,4, Kari Juhani Syrjanen5, Adhemar LongattoFilho1,3,4,6

1 Teaching and Research Institute, Barretos Cancer Hospital–Pio XII Foundation, Barretos, Sao Paulo, Brazil,

2 Department of Chest, Barretos Cancer Hospital–Pio XII Foundation, Barretos, Sao Paulo, Brazil,